Balto Pharmaceuticals Inc, based in South Pasadena, CA, is a drug discovery company specializing in small molecule inhibitors and degraders of protein-protein interactions (PPIs) for the treatment of cancer and other diseases. Their proprietary PP2D platform has enabled the discovery of first-in-class small molecules that inhibit and degrade critical drivers in cancer, potentially offering a new class of therapeutics.
With a focus on monovalent targeted protein degraders, Balto Pharmaceuticals' PPI inhibitors, isolated through their PP2D platform, show promise in disrupting and degrading PPIs, presenting a novel approach to treating various diseases. Their commitment to innovative drug discovery positions them at the forefront of developing transformative therapies.
Generated from the website